Today: 10 November 2025
Subscribe
Browse Category

NASDAQ:OMER News 15 October 2025 - 17 October 2025

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Stock Performance: Recent Surge and Volatility Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 (Oct 14 close) to $10.42 by Oct 15 close investor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal (see below). Trading volume was staggering: Benzinga reports ~89.2 million shares traded (vs. a ~1.1M daily average) during the rally benzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen
16 October 2025
 ·  ·  ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights investor.omeros.com reuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the news reuters.com, and by market close had settled near $10.10 investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcement ts2.tech. The deal is structured as an
15 October 2025
 ·  ·  ·  ·  ·  · 
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties novonordisk.com. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug reuters.com. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 marketscreener.com novonordisk.com. Novo’s Chief Scientific
15 October 2025
 ·  ·  ·  ·  ·  ·  · 
Go toTop